AIKI Research and Charts

AIKI - AIkido Pharma Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2023-06-30 (Delayed quote data 2025-07-03)

Last 5.27	Change ⇑ +0.02 (+0.38%)	Volume 72,855
	Open 5.36	High 5.40	Low 5.18

8EMA (Daily) 5.40	40EMA (Daily) 5.22	50EMA (Daily) 5.17	STO (Daily) 30.788	MACD Hist (Daily) -0.085
8EMA (Weekly) 5.253	40EMA (Weekly) 4.18	50EMA (Weekly) 3.93	STO (Weekly) 62.546	MACD Hist (Weekly) -0.101


Company Profile
AIkido Pharma Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing a antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.